Currently, the medical community considers the following three drugs available for biological treatment of lymphoma: Monoclonal antibodies: CD20-positive B-cell lymphoma can all be treated with CD20 monoclonal antibody melphalan (rituximab). Moreover, the use of rituximab for in vivo tumor cell decontamination prior to hematopoietic stem cell transplantation in B-cell lymphoma can greatly improve the efficacy of transplantation therapy. Interferon: Partial remission in mycosis fungoides and follicular small cracked cell type lymphoma. Anti-H. pylori drugs: Lymphomas in the marginal bands of mucosa-associated lymphoid tissue outside the gastric nodes can be improved and the lymphomas disappear in some patients after anti-H. pylori treatment.